EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable
Conditions
Keywords
non-small cell lung cancer, EGFR-mutant, Sacituzumab Tirumotecan, Limertinib
Brief summary
This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinical treatment plans and enabling patients to receive the optimal treatment regimen.
Interventions
DRUGSacituzumab Tirumotecan and Limertinib
Sacituzumab Tirumotecan injection is administered once every two weeks for a total of six treatments. Sacituzumab Tirumotecan injection: 4 mg/kg, intravenous infusion, Q2W. Limertinib is administered for 12 weeks. Limertinib: standard dose, oral, Qd. After the completion of the neoadjuvant treatment cycle, enhanced chest CT and other evaluations are conducted. The feasibility of radical surgery is assessed by MDT. Patients who are eligible for surgery will undergo surgical treatment, and the treatment plan for those who are not eligible for surgery will be determined after discussion by MDT.
Sponsors
Shanghai Pulmonary Hospital, Shanghai, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Sign the informed consent form * The age of the subjects is over 18 years old * Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology * Confirmed as locally advanced NSCLC (IIIA, IIIB, IIIC) by chest CT, PET-CT or/and EBUS, and MDT discussion concludes that immediate local surgery is not suitable * Have not received systematic anti-tumor treatment before * The researcher confirms at least one measurable lesion according to RECIST 1.1 criteria * Good lung function and able to tolerate surgical treatment * ECOG score is 0 to 1
Exclusion criteria
* Allergy to Sacituzumab Tirumotecan or any of its excipients * Patients allergic to Limertinib or any of its excipients * Patients with a history of other primary tumors; patients with a history of allogeneic organ transplantation * Major surgery within 4 weeks before the first dose (excluding diagnostic biopsy) * Patients with drug addiction such as drug abuse, long-term alcohol abuse, AIDS or HIV carriers * Patients with active or previously had and may recur autoimmune diseases * Currently receiving systemic hormone therapy (such as equivalent to more than 10 mg of prednisone per day or any other form of immunosuppressive therapy within 14 days before the first dose) * Patients who have received any EGFR-TKI or TROP2 ADC treatment before
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response (pCR) rate | Perioperative |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) | Up to 3 months |
| Event-free suvival (EFS) | Up to 60 months |
| Overall suvival (OS) | Up to 60 months |
| Major pathologic response (MPR) rate | Perioperative |
| Incidence of treatment discontinuation due to AE/SAE | Up to 3 months |
| Treatment-related adverse event (TRAE) | Up to 3 months |
| R0 resection rate | Perioperative |
Countries
China
Contacts
Primary ContactPeng Zhang, PhD
Outcome results
None listed